Arvinas (ARVN) vs Evolus (EOLS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Evolus (EOLS) has outperformed Arvinas (ARVN) over the past year, gaining 23.6% versus a loss of 19.9%. Over five years, EOLS leads with a +0.9% price change compared with -91.2% for ARVN. Evolus is the larger company by market cap ($511.2 million vs $480.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARVN | EOLS |
|---|---|---|
| Share price | $7.45 | $7.74 |
| Market cap | $480.68M | $511.23M |
| 1-day change | +1.92% | +4.88% |
| YTD return | -37.18% | +16.39% |
| 1-year return | -19.89% | +23.64% |
| 5-year return | -91.25% | +0.91% |
| P/E ratio (TTM) | 28.65 | — |
| Forward P/E | — | 26.46 |
| EPS (TTM) | $0.26 | $-0.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.51 | $9.31 |
| 52-week low | $6.97 | $3.86 |
| Distance from 52-week high | -48.66% | -16.86% |
| Analyst consensus | buy | none |
| Avg. price target upside | +86.98% | +93.80% |
| Average volume | 779.91K | 901.46K |
| Shares outstanding | 64.52M | 66.05M |
| Employees | 246 | 353 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EOLS has outperformed ARVN by 43.5 percentage points over the past year.
About Arvinas
ARVN stock →Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
Healthcare · Biotechnology · 246 employees
About Evolus
EOLS stock →Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes.
Healthcare · Drug Manufacturers - Specialty & Generic · 353 employees
ARVN vs EOLS FAQ
Which is bigger, Arvinas or Evolus?
Evolus (EOLS) is larger, with a market capitalization of $511.23M compared with $480.68M for Arvinas (ARVN).
Which stock has performed better over the past year, ARVN or EOLS?
EOLS returned +23.64% over the past 12 months, compared with -19.89% for ARVN (price return, excluding dividends). Past performance does not predict future results.
Are Arvinas and Evolus in the same industry?
Both are in the Healthcare sector, but in different industries: Biotechnology for Arvinas and Drug Manufacturers - Specialty & Generic for Evolus.